Caricamento...

Prevention of Bone Loss with Risedronate in Breast Cancer Survivors: A Randomized, Controlled Clinical Trial

PURPOSE: Aromatase inhibitors (AIs), adjuvant endocrine therapy for postmenopausal women with hormone receptor positive breast cancer, are associated with bone loss and fractures. Our objectives were to determine if 1) oral bisphosphonate therapy can prevent bone loss in women on an AI and, 2) early...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Osteoporos Int
Autori principali: Greenspan, Susan L., Vujevich, Karen T., Brufsky, Adam, Lembersky, Barry C., van Londen, G.J., Jankowitz, Rachel C., Puhalla, Shannon L., Rastogi, Priya, Perera, Subashan
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4766869/
https://ncbi.nlm.nih.gov/pubmed/25792492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-015-3100-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !